AppleW
2021-08-26
看来这支股票要涨啊
众巢医学布局卵巢癌市场,医药行业又一片新蓝海?
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
山谷来风
2021-08-26
山谷来风
真的假的? 不过这支股票价格的确不高。
AppleW
:
当然不高了,众巢医学 绝对是潜力股。
什么也没有了~
APP内打开
发表看法
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":810669772,"tweetId":"810669772","gmtCreate":1629972510396,"gmtModify":1629972510396,"author":{"id":3537159488676899,"authorId":3537159488676899,"authorIdStr":"3537159488676899","name":"AppleW","avatar":"https://static.tigerbbs.com/03a4df2e4c49dab2c68408d77c565982","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>看来这支股票要涨啊</p></body></html>","htmlText":"<html><head></head><body><p>看来这支股票要涨啊</p></body></html>","text":"看来这支股票要涨啊","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/810669772","repostId":2162706267,"repostType":2,"repost":{"id":"2162706267","pubTimestamp":1629959373,"share":"https://www.laohu8.com/m/news/2162706267?lang=&edition=full","pubTime":"2021-08-26 14:29","market":"us","language":"zh","title":"众巢医学布局卵巢癌市场,医药行业又一片新蓝海?","url":"https://stock-news.laohu8.com/highlight/detail?id=2162706267","media":"美股研究社","summary":"美股研究社获悉,据智通财经消息,众巢医学8月26日宣布,其子公司上海众芯医疗科技有限公司为择优乐享-患者援助项目的卵巢癌患者提供随访管理服务,帮助卵巢癌患者提高治疗效果,并最终提高生存率。另外,一体化系统中的数字随访功能允许患者管理专员和医生对患者进行一对一用药指导和生活方式建议,确保患者正确地用药和应对不良反应,从而改善治疗体验。","content":"<html><body><article><p>美股研究社获悉,据智通财经消息,<a href=\"https://laohu8.com/S/ZCMD\">众巢医学</a>(ZCMD.US)8月26日宣布,其子公司上海众芯医疗科技有限公司(简称“众芯医疗”)为择优乐享-患者援助项目(简称“项目”)的卵巢癌患者提供随访管理服务,帮助卵巢癌患者提高治疗效果,并最终提高生存率。</p><img src=\"https://fid-75186.picgzc.qpic.cn/20210826145745990d1546f3mlgya5ui\"/><p>项目由白求恩慈善基金会管理,向符合尼拉帕利,一种抗癌药物,适应症的中国女性患者提供援助。通过公司自主研发的一体化患者管理服务系统(简称“一体化系统”),患者可以记录,追踪和查看自己用药过程中的身体和疾病的各项指标,并收到潜在疾病进展的预警,以管理用药期间出现的不良反应和心理问题,并提高她们的诊疗依从性及治疗安全性。另外,一体化系统中的数字随访功能允许患者管理专员和医生对患者进行一对一用药指导和生活方式建议,确保患者正确地用药和应对不良反应,从而改善治疗体验。根据GlobalData的数据,2018年美国、法国、德国、意大利、西班牙、英国和日本七个主要市场的卵巢癌市场规模为18亿美元,预计未来十年将增长到67亿美元,年复合增长率为14.4%。</p><p></p></article></body></html>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>众巢医学布局卵巢癌市场,医药行业又一片新蓝海?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n众巢医学布局卵巢癌市场,医药行业又一片新蓝海?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-26 14:29 北京时间 <a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202108261457467a5a5026&s=b><strong>美股研究社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>美股研究社获悉,据智通财经消息,众巢医学(ZCMD.US)8月26日宣布,其子公司上海众芯医疗科技有限公司(简称“众芯医疗”)为择优乐享-患者援助项目(简称“项目”)的卵巢癌患者提供随访管理服务,帮助卵巢癌患者提高治疗效果,并最终提高生存率。项目由白求恩慈善基金会管理,向符合尼拉帕利,一种抗癌药物,适应症的中国女性患者提供援助。通过公司自主研发的一体化患者管理服务系统(简称“一体化系统”),患者...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202108261457467a5a5026&s=b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636","relate_stocks":{"ZCMD":"众巢医学"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202108261457467a5a5026&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2162706267","content_text":"美股研究社获悉,据智通财经消息,众巢医学(ZCMD.US)8月26日宣布,其子公司上海众芯医疗科技有限公司(简称“众芯医疗”)为择优乐享-患者援助项目(简称“项目”)的卵巢癌患者提供随访管理服务,帮助卵巢癌患者提高治疗效果,并最终提高生存率。项目由白求恩慈善基金会管理,向符合尼拉帕利,一种抗癌药物,适应症的中国女性患者提供援助。通过公司自主研发的一体化患者管理服务系统(简称“一体化系统”),患者可以记录,追踪和查看自己用药过程中的身体和疾病的各项指标,并收到潜在疾病进展的预警,以管理用药期间出现的不良反应和心理问题,并提高她们的诊疗依从性及治疗安全性。另外,一体化系统中的数字随访功能允许患者管理专员和医生对患者进行一对一用药指导和生活方式建议,确保患者正确地用药和应对不良反应,从而改善治疗体验。根据GlobalData的数据,2018年美国、法国、德国、意大利、西班牙、英国和日本七个主要市场的卵巢癌市场规模为18亿美元,预计未来十年将增长到67亿美元,年复合增长率为14.4%。","news_type":1},"isVote":1,"tweetType":1,"viewCount":1105,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":18,"xxTargetLangEnum":"ZH_CN"},"commentList":[{"id":5655185,"gmtCreate":1629972878310,"gmtModify":1629972878310,"authorId":3537218695872534,"author":{"id":3537218695872534,"authorId":3537218695872534,"name":"山谷来风","avatar":"https://static.tigerbbs.com/e25745082a175af4e9f814d2e9d3bd37","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":810669772,"type":1,"supId":0,"prevId":0,"content":"真的假的? 不过这支股票价格的确不高。","text":"真的假的? 不过这支股票价格的确不高。","html":"真的假的? 不过这支股票价格的确不高。","likeSize":0,"commentSize":1,"subComments":[{"id":5655229,"gmtCreate":1629973196311,"gmtModify":1629973196311,"authorId":3537159488676899,"author":{"id":3537159488676899,"authorId":3537159488676899,"name":"AppleW","avatar":"https://static.tigerbbs.com/03a4df2e4c49dab2c68408d77c565982","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":810669772,"type":1,"supId":5655185,"prevId":0,"content":"当然不高了,众巢医学 绝对是潜力股。","text":"当然不高了,众巢医学 绝对是潜力股。","html":"当然不高了,众巢医学 绝对是潜力股。"}],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/810669772"}
精彩评论